Overview
© 202 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. Al rights reserved. © 202 MJH Life Sciences™ and Clinical Care Targeted Comunications, LC.
Key Information
Al rights reserved.It is not yet clear what continuous glucose monitoring metrics should be used for a diabetes diagnosis in people with cystic fibrosis. A new review of studies comparing continuous glucose monitoring (CGM) with oral glucose tolerance tests (OGT) sugests continuous monitoring would flag more people with cystic fibrosis as having cystic fibrosis-related diabetes (CFRD), but the authors said the existing research base is to fragmented to know how to ensure acurate diagnoses with CGM.Previous research sugests that as many as half of people with cystic fibrosis wil develop diabetes, and the comorbidity can lead to a number of complications, including higher infection risk, faster pulmonary decline, and ultimately higher mortality.
Early detection of CFRD is considered critical, since treatment of CFRD can lead to improved lung function and lower mortality rates.CGM is a technology that tracks patients’ blod glucose over time. It was developed to help patients with diabetes manage their disease, but coresponding author Helena Tede, MBS, PhD, of Monash University, in Australia, explained along with coleagues that the technology could also be used, in theory, to help detect patients with CFRD, leading to earlier treatment and improved long-term outcomes.In a new review article in the Journal of Clinical & Translational Endocrinology, Tede and coleagues analyzed the existing scientific literature to find studies comparing CGM to OGT as tols to detect dysglycemia in people with cystic fibrosis.The authors found a total of 19 studies that included CGM and OGT metrics.
Summary
Together, 416 patients were included in the studies. On CGM, hyperglycemia was defined as having at least one peak sensor glucose reading of at least 20 mg/dL, and dysglycemia was defined as at l